A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Active:	No
Cancer Type:	Lung Cancer	NCT ID:	NCT04513925
Trial Phases:	Phase III	Protocol IDs:	GO41854 (primary) NCI-2020-07791 2019-004773-29
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT04513925

Summary

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in
combination with tiragolumab compared with durvalumab in participants with locally
advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at
least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had
radiographic disease progression.

Treatment Sites in Georgia

Northwest Georgia Oncology Centers - Cobb Hospital (Hiram)
144 Bill Carruth Parkway
Suite 3100
Hiram, GA 30141
770-281-5131
www.ngoc.com

Doctors:

Kathleen A. Long MD

Aron E. Kefela MD

Northwest Georgia Oncology Centers - Tanner Medical Center Villa Rica
157 Clinic Avenue
Suite 101 and Suite 102
Carrollton, GA 30117
770-281-5101
www.ngoc.com

Doctors:

Bradley J.G. Larson MD

Randall E. Pierce MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.